Interim results show AB-101a significantly controls atopic dermatitis skin bacteria
Click Here to Manage Email Alerts
Key takeaways:
- 80% of patients achieved an itch score improvement of 4 points or more.
- 90% of patients achieved EASI 50 and 44% achieved EASI 75.
Alphyn Biologics presented interim data from the second cohort of its phase 2a clinical trial program of AB-101a for the treatment of atopic dermatitis, according to a presentation at the Society for Pediatric Dermatology annual meeting.
“The interim results of the second cohort of the phase 2a trial are significant because they demonstrate that patients suffering from mild, moderate and severe AD with and after associated secondary bacterial infection could be effectively treated with AB-101a, see their symptoms significantly improve, their infections cleared and the bacterial microbiome on their AD skin controlled to prevent AD flares caused by bacteria,” Neal Koller, CEO of Alphyn Biologics, told Healio.
Following the release of data from its first cohort, these interim results, compiled from seven to 10 patients, showed that 80% of patients achieved an itch score improvement of 4 points or more.
Additionally, 90% of patients achieved EASI 50 and 44% achieved EASI 75. An IGA score of clear or almost clear was reached by 64% of patients, whereas a 2-point or greater improvement was reached by 40% of patients.
All patients reported a clearing of their infections, with 82% achieving an improvement of at least 6 points on the Skin Infection Rating Scale (SIRS), or an improvement of 55% to 75%.
AB-101a demonstrated control of the AD skin bacterial microbiome and AD flares caused by bacteria as evidenced by the fact that all patients’ SIRS scores steadily decreased over time. According to a company press release, this effectiveness is equivalent to treatment with vancomycin, the “gold-standard” for bacterial infection treatment and prevention.
One treatment-emergent adverse event was reported.
“There is no similar therapeutic on the market that is suitable for long-term continuous use that treats the bacterial and immune components of the disease and is effective for all severity levels of AD,” Koller told Healio. “While these data are early, we are very encouraged by the results and look forward to further evaluating AB-101a in a phase 2b trial.”
The second cohort has completed enrollment and is expected to conclude with 19 patients.
Reference:
Read more about
Click Here to Manage Email Alerts